Benefits, Risks and Stakeholder Impact
Positive Impact
Faster patient access
Expedited regulatory pathways in 2026 have had a clear positive impact on the pharmaceutical market by significantly accelerating patient access to critical therapies. Programs such as Fast Track, Breakthrough Therapy Designation, Priority Review, and Accelerated Approval have enabled promising drugs—particularly those in oncology and rare diseases—to reach patients much earlier than would be possible through traditional approval timelines. This has directly contributed to a reduction in time to market, allowing life-saving and high-impact treatments to be available months, and in some cases years, ahead of standard review processes. As a result, patients with serious and unmet medical needs are gaining earlier access to innovative therapies, while companies benefit from faster commercialisation, improved return on investment, and extended market exclusivity windows. Overall, expedited designations in 2026 have strengthened the balance between regulatory rigour and speed, fostering a more responsive healthcare ecosystem and driving innovation across the biopharmaceutical industry.
Few notables’ examples were:
Here are a few notable 2026 examples that clearly show how expedited designations improved faster patient access and reduced time to market:
1. Tecvayli + Darzalex (Johnson & Johnson) – Multiple Myeloma
In March 2026, the FDA approved Tecvayli in combination with Darzalex for relapsed multiple myeloma under the FDA’s National Priority Voucher Program. The approval was granted in just 55 days after filing, compared to the usual 10–12 months, significantly accelerating patient access to treatment. This also converted Tecvayli’s earlier accelerated approval into full approval, strengthening commercial confidence and market expansion.
2. Zongertinib (Hernexeos) – HER2-Mutated NSCLC
Zongertinib received accelerated approval in early 2026 for newly diagnosed HER2-mutated non-small cell lung cancer patients. Previously limited to pretreated patients, this expanded approval allowed earlier-line treatment access, improving both patient outcomes and the product’s commercial opportunity by expanding the eligible patient population.
3. Relacorilant (Lifyorli) – Platinum-Resistant Ovarian Cancer
Relacorilant received FDA approval as a first-in-class treatment for platinum-resistant ovarian cancer in 2026. Its expedited pathway helped bring a novel mechanism to patients faster, addressing a major unmet need where treatment options were limited. This also created strong market differentiation for the sponsor through first-mover advantage.
4. Rilzabrutinib – Warm Autoimmune Hemolytic Anemia (wAIHA)
Rilzabrutinib received Breakthrough Therapy Designation in February 2026, helping accelerate development for this rare autoimmune disease with limited treatment options. Breakthrough designation provides intensive FDA guidance and rolling review potential, reducing development risk and improving investor confidence.
“Expedited regulatory pathways in 2026 transformed the pharmaceutical landscape by turning breakthrough therapies into faster patient access, shorter time-to-market, and accelerated innovation across oncology, rare diseases, and beyond.”
“Expedited regulatory designations in 2026 became a catalyst for biopharmaceutical innovation, accelerating investment, pipeline growth, and breakthrough therapies across oncology, rare diseases, and advanced genetic medicines.”
Innovation boost
In 2026, expedited regulatory designations such as Fast Track, Breakthrough Therapy Designation, Priority Review, Accelerated Approval, and Orphan Drug Designation played a major role in driving innovation across the biopharmaceutical market, particularly in high-risk therapeutic areas like oncology and rare diseases. These pathways provided developers with faster regulatory guidance, shorter review timelines, and stronger commercial incentives, making investment in complex and high-uncertainty drug programs more attractive.
This has significantly encouraged R&D in areas with high unmet medical need, where traditional development risks are often higher due to small patient populations, complex clinical endpoints, and limited precedent. Rare genetic disorders, hematologic cancers, and precision oncology therapies have especially benefited, with many companies prioritizing novel biologics, cell and gene therapies, and targeted treatments because expedited pathways improve both development efficiency and market viability.
As a result, 2026 has seen stronger pipeline expansion, increased biotech investment, and greater strategic focus on first-in-class and breakthrough therapies, reinforcing expedited designations as a key driver of pharmaceutical innovation.
Notable 2026 Examples Showing Innovation Boost from Expedited Designations
1. Rilzabrutinib (Sanofi) – Warm Autoimmune Hemolytic Anaemia (wAIHA)
In February 2026, rilzabrutinib received FDA Breakthrough Therapy Designation for warm autoimmune hemolytic anemia, a rare autoimmune disorder with no approved targeted therapy. It also received orphan designation in Japan for the same indication. This designation accelerated development by providing intensive FDA guidance and strengthened Sanofi’s investment in rare immune-mediated diseases, highlighting how expedited pathways encourage R&D in underserved rare disease markets.
2. NGN-401 (Neurogene) – Rett Syndrome
NGN-401 received Breakthrough Therapy Designation in February 2026 for Rett Syndrome, a rare neurodevelopmental disorder with limited treatment options. This recognition increased visibility for advanced gene therapy development in rare pediatric diseases and reinforced investor confidence in high-risk neurological R&D programs.
3. Nomlabofusp (Larimar Therapeutics) – Friedreich’s Ataxia
Nomlabofusp was granted Breakthrough Therapy Designation for Friedreich’s Ataxia in 2026, supporting continued innovation in rare genetic disorders. Since these diseases often have small patient populations and high development risk, expedited designation significantly improves commercial viability and encourages further biotech investment.
4. Amivantamab + Hyaluronidase (Johnson & Johnson) – Advanced Head and Neck Cancer
This oncology combination therapy received Breakthrough Therapy Designation in 2026 for advanced head and neck cancer. Oncology continues to be the largest beneficiary of expedited pathways, and such designations help companies prioritize biomarker-driven therapies and next-generation targeted treatments by reducing regulatory uncertainty and development timelines.
Challenges & Risks
Clinical Uncertainty
Expedited approvals in 2026 frequently relied on early-stage clinical data, surrogate endpoints, or smaller patient populations. While this enabled faster access to innovative therapies, it also introduced uncertainty regarding long-term efficacy and durability of response. In several cases, full clinical benefit was not completely established at the time of approval, requiring ongoing real-world evidence generation after launch.
Safety Concerns
Because many drugs entered the market with limited pre-approval exposure, there was a higher likelihood of post-marketing safety findings. This led to increased reliance on pharmacovigilance systems, safety database expansion, and regulatory label updates after commercialisation. In some cases, rare adverse events only emerged once broader patient populations were exposed.
Confirmatory Trial Delays
A recurring challenge in 2026 was delays in completing required post-approval confirmatory trials, particularly for therapies approved under Accelerated Approval pathways. These delays created gaps between early market access and full verification of clinical benefit, raising concerns about sustained regulatory confidence and long-term approval status in certain cases.
Pricing Pressures
Expedited approvals, particularly in oncology and rare diseases, were often associated with high launch prices due to the small patient populations and significant R&D investments. While these therapies addressed critical unmet needs, they intensified pricing pressure on payers, reimbursement systems, and healthcare budgets, raising ongoing discussions around affordability and value-based pricing models.
“While expedited approvals in 2026 accelerated access to breakthrough therapies, they also heightened challenges around clinical uncertainty, post-market safety monitoring, confirmatory trial delays, and growing pricing pressures on global healthcare systems.”
Impact on Stakeholders
Expedited pathways in 2026 drove faster commercialization and innovation—but came with tighter regulatory oversight.”
Pharma Companies
Expedited designations in 2026 have helped pharmaceutical companies accelerate commercialisation by reducing development and review timelines through Fast Track, Breakthrough Therapy, Priority Review, and Accelerated Approval pathways. This allows earlier market entry, faster revenue generation, and stronger investor confidence—especially in oncology, rare diseases, and speciality therapies. However, companies also face greater regulatory scrutiny, frequent FDA interactions, and strict post-marketing commitments such as confirmatory trials.
A notable example is HYMPAVZI by Pfizer, which received FDA Priority Review in February 2026 for expanding its indication in haemophilia A and B patients. If approved, it could become the first non-factor prophylactic treatment for children aged 6–11 with haemophilia B, demonstrating a strong commercial opportunity but also requiring robust long-term evidence.
Regulators
For regulators such as the U.S. Food and Drug Administration, the growing number of expedited approvals has significantly increased workload and operational complexity. Review teams must maintain high scientific standards while working within compressed review timelines. In addition, accelerated approvals require stronger post-market monitoring, confirmatory trial oversight, and enforcement if sponsors fail to verify clinical benefit.
The 2026 Institute for Clinical and Economic Review white paper on strengthening the FDA’s Accelerated Approval pathway emphasised that confirmatory trial delays and withdrawals remain major regulatory concerns. It highlighted examples such as bevacizumab’s withdrawal history to show how regulators must actively manage approvals even after market entry.
The FDA’s growing list of novel drug approvals in Q1 2026—including 11 approvals by April—also reflects this increased review burden across oncology, metabolic disease, and rare disorders.
“Expedited approvals in 2026 drove access—but raised the bar for regulators, demanding faster reviews, stronger surveillance, and continuous oversight.''
“Expedited pathways in 2026 improved early access in high‑unmet‑need diseases—but raised uncertainty around long‑term clinical outcomes.”
Patients
Patients benefit most directly from expedited pathways through earlier access to potentially life-saving treatments, particularly in diseases with high unmet need such as rare diseases, oncology, and haematology. These pathways reduce waiting time and provide treatment options where no approved alternatives may exist.
A notable example of 2026 is Avlayah, approved in March 2026 for paediatric patients with Hunter syndrome. This approval gave earlier access to treatment for a rare neurologic disease with limited options, significantly improving care opportunities for affected children.
Similarly, Yuviwel was approved in February 2026 for children with achondroplasia, offering earlier intervention for growth management. However, many such approvals rely on surrogate endpoints or limited datasets, meaning long-term efficacy and safety may remain uncertain after launch.
Payers
Payers face major cost-effectiveness challenges as many expedited drugs launch with premium pricing despite limited long-term clinical outcomes data. Since approvals are often based on surrogate endpoints rather than confirmed survival or quality-of-life improvements, reimbursement decisions become more complex and risk-sensitive.
For example, rare disease and speciality drugs such as Loargys for Arginase 1 Deficiency and Avlayah for Hunter syndrome entered the market in 2026 with high expected treatment costs and limited patient populations, creating reimbursement pressure for insurers and health systems.
ICER’s 2026 report also emphasised that payers increasingly prefer linking reimbursement decisions to confirmatory evidence quality and may push for value-based pricing models until stronger long-term outcomes are established.
“Expedited approvals in 2026 intensified payer pressure, with high‑cost therapies and limited long‑term data driving greater reliance on value‑based reimbursement.”